Pharmaceutical
StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
StemRIM Announces Patent Registration (Russia) for Redasemtide, as a Therapeutic Indication for Fatty Liver and Non-alcoholic Steatohepatitis
About this update from Stemrim Inc.
Stemrim Inc. (4599) Press ReleaseView Attachment